 "WHO suspends Anuh Pharma's products from prequalified list")
Anuh Pharma on Thursday said that the World Health Organisation (WHO) has suspended its products – Pyrazinamide and Sulfadoxine – from prequalified list of active pharmaceutical ingredients (API).
The WHO's move comes in the wake of European Directorate for the Quality of Medicines and Healthcare (EQDM) suspending certificate of suitability for the drug firm's three products last month after conducting an inspection of its manufacturing site at Boisar in Maharashtra.
"In view of the EDQM suspension, the WHO pre-qualification authorities have suspended Pyrazinamide and Sulfadoxine from the WHO list of prequalified API's until the WHO led inspection," Anuh Pharma said in a regulatory filing.
Pre-qualification is a process under which drug companies have to fulfil certain WHO-stipulated conditions to become eligible to supply vaccines to UN procurement agencies globally.
Shares of Anuh Pharma were trading at Rs 172.20 on BSE, down 2.10 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%